Research

The USF Parkinson's Disease & Movement Disorders Center has been involved in the evaluation and development of almost every new medication and surgical procedure for Parkinson's Disease in the last 20 years. Multiple independent and sponsored studies are conducted at our center. Dr. Hauser's research work has included the development of clinical trial designs and outcome measures, evaluation of cell transplant therapies, and the development of new medical and surgical therapies. Dr. Hauser is lead investigator for national and international clinical trials and serves on steering committees for several drug development programs and clinical trials.

You may qualify for enrollment in one of the following clinical trials. Please be advised that each clinical trial has certain criteria and a screening visit for qualification is required.

If you would like further information regarding our current and future Research please contact Sherry Harlan, Research Administrator at 813 844-8568.

Parkinson's Progression Markers Initative for Early PD and Healthy Controls
Age group: 30 years or older	Length of study: 3 -5 years	Holly Delgado	844-4453
Phase 3, double-blind, Placebo and active-controlled study of Preladenant in subjects with early Parkinson's Disease. Must have a PD diagnosis of less than 3 years
Age group: 30-80 years	Length of Study: 28 weeks (1 year extension trial available)	Patti Lowe	844-4466
A randomized study to assess safety and clinical benefit of Rasagiline as an add on therapy to stable does of dopamine agonists in treatment of early Parkinson's Disease. Selegiline not allowed
Age group: 30 years or older	Length of study: 18 weeks	Leyla Khavarian	844-4477
A study to evaluate the responsiveness of a variety of available dyskinesia rating scales with amantadine vs. placebo. Must be on a stable dose of PD meds for at least 4 weeks
Age group: 30-90 years	Length of study: 8 weeks	Leyla Khavarian	844-4477
Parkinson's Disease patients with orthostatic hypotention
Age group: 18 years or older	Length of study: 14 weeks	Holly Delgado	844-8568
Adavanced Parkinson's Disease patients experiencing disabling "off" episodes
Age group: 18 years or older	Length of study: 84 days	Patti Lowe	844-4466
A Phase 3 study for Parkinson's Disease patients diagnosed at least one year experiencing hallucinations
Age group: 40 years or older	Length of study: 6 weeks with 4 week follow-up and open label extension	Gerry Piper	844-8069
A double-blind, open-label study for Parkinson's Disease patients with congnitive impairment. Cannot have diagnosis of dementia
Age group: 45-80 years	Length of study: 6 months to 1 year	Claudia Rocha	844-8068
Phase 3 clinical trial Resonator Device for Parkinson's Disease patients. Must be able to travel to Clearwater site for 8 week treatments
Age group: 35-85 years	Length of study: 12 weeks	Leyla Khavarian	844-4477
Observational study designed to capture current diagnosis and treatment approaches for cervical dystonia and their effects on patients
Age group: Open	Length of study: 10 months ( 3 injections, plus 1 follow-up visit)	Claudia Rocha	844-8068
Brain Fitness and Parkinson's Disease. To evaluate if a computerized brain fitness program is effective at enhancing thinking and everyday abilities of older adults
Age group: 40 years or older	Length of study: 6 moths to 1 year	Holly Delgado	844-4453
A phase 2 randomized, double-blinded, placebo controlled study to investigate COGANE for subjects with early stage Parkinson's Disease. Must be in early stage, untreated for PD.
Age group: 35 - 75 years	Length of study: 32 weeks	Patti Lowe	844-4466